G&E Business Summary

G&E Herbal Biotechnology Co., Ltd. (4911.TWO) is a Taiwan-based biopharmaceutical firm specializing in the research, development, and commercialization of botanical drugs and health products. The company generates revenue through three primary business segments: botanical pharmaceuticals, health supplements, and functional skincare. Its flagship products include Hepanamin® for liver protection and the SR-100 series, which utilizes a patented botanical extraction technology for applications in oncology (SR-T100 gel), anti-aging cosmetics, and specialized lubricants. Operating out of PIC/S GMP-certified facilities in Tainan, the company leverages a vertically integrated model from raw material extraction to clinical development. Within the competitive landscape of Taiwan’s biotech sector, G&E competes directly with Maywufa Co., Ltd. (1731), Li Kang Biomedical (6242), and DR.Wu Skincare (6523). G&E distinguishes itself through its focus on high-barrier botanical drug innovation and a robust international patent portfolio that bridges traditional herbal medicine with modern clinical therapeutics. The company is led by Chairman and CEO Professor Kou-Wha Kuo, a prominent academic who served for 23 years at the Institute of Biochemistry at Kaohsiung Medical University before founding G&E in 2002. Under his leadership, the firm has transitioned from a research-centric enterprise into a publicly traded entity on the Taipei Exchange. The executive team is supported by a board of directors that includes independent members Jun Nong Huang, Li Wei Lin, and Zhicong Lin, who provide oversight on corporate governance and strategic expansion. G&E’s pedigree is rooted in interdisciplinary scientific collaboration, with a core research team spanning pharmacology, molecular biology, and biochemistry, which has earned the company multiple accolades including the National Invention and Creation Award and the Gold Medal in Pharmaceutical Technology.